Coherus BioSciences Announces New Employment Inducement Grants
October 21 2016 - 9:00AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that
effective October 20, 2016, the compensation committee of the
company’s board of directors granted 5 new employees options to
purchase an aggregate of 62,000 shares of the company’s common
stock with a per share exercise price of $30.39, the closing
trading price on the grant date. The stock options were
granted pursuant to the Coherus BioSciences, Inc. 2016 Employment
Commencement Incentive Plan, which was approved by the company’s
board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq
Global Select Market for equity grants to induce new employees to
enter into employment with the company.
About Coherus BioSciences, Inc. Coherus is a
leading global biosimilar platform company that develops and
commercializes high-quality therapeutics for major regulated
markets. Biosimilars are intended for use in place of existing,
branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production and clinical-regulatory
development, Coherus is positioned as a leader in the global
biosimilar marketplace. Coherus is advancing three late-stage
clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products in four therapeutic areas, oncology,
immunology (anti-TNF), ophthalmology and multiple sclerosis. For
additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024